ABT-737

For research use only. Not for use in humans.

目录号：S1002

CAS No. 852808-04-9

ABT-737是一种BH3模拟抑制剂，作用于Bcl-xL，Bcl-2和Bcl-w，无细胞试验中EC50分别为78.7 nM，30.3 nM和197.8 nM；但对Mcl-1， Bcl-B及Bfl-1没有抑制作用。ABT-737可诱导线粒体通路的凋亡和线粒体自噬。Phase 2。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 3144.65	现货
5mg	RMB 972.14	现货
10mg	RMB 1647.36	现货
50mg	RMB 4659.22	现货
100mg	RMB 7964.03	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的ABT-737发表文献272篇：

Cell, 2018, 175(2):429-441

PubMed: 30245008 ( click the link to review the publication )

Cancer Cell, 2018, 33(3):435-449

PubMed: 29533784 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Nat Methods, 2017, 14(9):891-896

PubMed: 28737741 ( click the link to review the publication )

Nature, 2016, 529(7586):413-417

PubMed: 26735014 ( click the link to review the publication )

Nat Med, 2013, 19(11):1478-88

PubMed: 24141421 ( click the link to review the publication )

Nat Biotechnol, 2011, 29(6):542-6

PubMed: 21623355 ( click the link to review the publication )

ACS Nano, 2020, 14(3):3378-3388

PubMed: 32083466 ( click the link to review the publication )

Nat Commun, 2020, 11(1):259

PubMed: 31937780 ( click the link to review the publication )

Sci Adv, 2020, 6(34):eaba8968

PubMed: 32937365 ( click the link to review the publication )

EMBO J, 2020, e105071

PubMed: 32840892 ( click the link to review the publication )

Cancer Res, 2020, 10.1158/0008-5472.CAN-19-1784

PubMed: 32005716 ( click the link to review the publication )

Elife, 2020, 2;9:e54954

PubMed: 32484436 ( click the link to review the publication )

Cancers (Basel), 2020, 10;12(2) pii: E406

PubMed: 32050632 ( click the link to review the publication )

Mol Cancer Ther, 2020, 5;molcanther.510.2019

PubMed: 32371581 ( click the link to review the publication )

Allergy Asthma Immunol Res, 2020, 12(4):608-625

PubMed: 32400128 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0669

PubMed: 32238439 ( click the link to review the publication )

Sci Rep, 2020, 20;10(1):687

PubMed: 31959760 ( click the link to review the publication )

Cancer Cell Int, 2020, 20:405

PubMed: 32863764 ( click the link to review the publication )

Biomed Pharmacother, 2020, 126:110040

PubMed: 32145585 ( click the link to review the publication )

Ann Transl Med, 2020, 8(6):364

PubMed: 32355808 ( click the link to review the publication )

Eur J Pharm Sci, 2020, 142:105105

PubMed: 31669390 ( click the link to review the publication )

Platelets, 2020, 10.1080/09537104.2020.1724276

PubMed: 32079453 ( click the link to review the publication )

Cell Death Differ, 2020, 10.1038

PubMed: 32015503 ( click the link to review the publication )
Environ Toxicol, 2020, 10.1002

PubMed: 32061152 ( click the link to review the publication )

Cell Rep, 2020, 32(1):107845

PubMed: 32640215 ( click the link to review the publication )

Life Sci Alliance, 2020, 28;3(6) pii: e202000735

PubMed: 32345661 ( click the link to review the publication )

Transfusion, 2020, 60(4):806-814

PubMed: 32159862 ( click the link to review the publication )

PLoS One, 2020, 15(7):e0234103

PubMed: 32645016 ( click the link to review the publication )

Infect Immun, 2020, 10.1128/IAI.00851-19

PubMed: 32179584 ( click the link to review the publication )

Aging (Albany NY), 2020, 12(14):14174-14188

PubMed: 32692721 ( click the link to review the publication )

Cell Death Dis, 2020, 11(1):8

PubMed: 31907357 ( click the link to review the publication )

Mol Cell, 2019, 74(1):19-31

PubMed: 30878284 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5770

PubMed: 31852899 ( click the link to review the publication )

EMBO J, 2019, 15;38(10):e101638

PubMed: 30902848 ( click the link to review the publication )

EMBO J, 2019, 38(11)

PubMed: 30979778 ( click the link to review the publication )

Dev Cell, 2019, 51(2):277-291

PubMed: 31564612 ( click the link to review the publication )

Cancer Res, 2019, 79(9):2339-2351

PubMed: 30862722 ( click the link to review the publication )

Cell Rep, 2019, 27(12):3657-3671

PubMed: 31216482 ( click the link to review the publication )

Cell Rep, 2019, 27(3):820-834

PubMed: 30995479 ( click the link to review the publication )

Br J Pharmacol, 2019, 176(3):436-450

PubMed: 30427531 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31540244 ( click the link to review the publication )

Cancers (Basel), 2019, 11(12)

PubMed: 31810230 ( click the link to review the publication )

Cell Death Dis, 2019, 10(2):121

PubMed: 30741926 ( click the link to review the publication )

J Cancer, 2019, 10(6):1466-1478

PubMed: 31031856 ( click the link to review the publication )

Thromb Haemost, 2019, 19(10):1665-1674

PubMed: 31493778 ( click the link to review the publication )

Oxid Med Cell Longev, 2019, 2019:5820415

PubMed: 31885804 ( click the link to review the publication )

Eur J Immunol, 2019, 10.1002/eji.201948254

PubMed: 31411729 ( click the link to review the publication )
Mol Pharmacol, 2019, 96(4):419-429

PubMed: 31467029 ( click the link to review the publication )

Phytomedicine, 2019, 64:153068

PubMed: 31419729 ( click the link to review the publication )

Phytomedicine, 2019, 52:147-156

PubMed: 30599894 ( click the link to review the publication )

Chem Biol Interact, 2019, 309:108723

PubMed: 31228469 ( click the link to review the publication )

J Bone Oncol, 2019, 19:100268

PubMed: 31832331 ( click the link to review the publication )

J Bone Oncol, 2019, 15:100222

PubMed: 30766792 ( click the link to review the publication )

PLoS One, 2019, 14(12):e0225977

PubMed: 31826021 ( click the link to review the publication )

Onco Targets Ther, 2019, 12:897-906

PubMed: 30774376 ( click the link to review the publication )

Platelets, 2019, 30(1):75-80

PubMed: 29125379 ( click the link to review the publication )

Am J Respir Crit Care Med, 2019, 200(1):84-97

PubMed: 30649895 ( click the link to review the publication )

Immunity, 2018, 48(4):675-687

PubMed: 29653696 ( click the link to review the publication )

Nat Commun, 2018, 9(1):5435

PubMed: 30575733 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(21):5458-5470

PubMed: 30021909 ( click the link to review the publication )

Oncogene, 2018, 37(39):5325-5339

PubMed: 29858601 ( click the link to review the publication )

Oncogene, 2018, 37(33):4599-4610

PubMed: 29755130 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):944

PubMed: 30237504 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):123

PubMed: 29374144 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):994

PubMed: 30250198 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):199

PubMed: 29415991 ( click the link to review the publication )

Cell Death Dis, 2018, 92(10)

PubMed: 23640461 ( click the link to review the publication )

Biochim Biophys Acta Mol Cell Res, 2018, 1865(3):522-531

PubMed: 29278689 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(6):935-946

PubMed: 29545477 ( click the link to review the publication )

Antioxidants (Basel), 2018, 10.3390/antiox7110150

PubMed: 30373097 ( click the link to review the publication )

Int J Oncol, 2018, 53(3):1055-1068

PubMed: 30015875 ( click the link to review the publication )
Cancer Biol Ther, 2018, 19(6):465-474

PubMed: 29394130 ( click the link to review the publication )

Phytother Res, 2018, 32(6):1126-1134

PubMed: 29464855 ( click the link to review the publication )

Thromb Res, 2018, 171:22-30

PubMed: 30240944 ( click the link to review the publication )

Environ Mol Mutagen, 2018, 59(1):49-59

PubMed: 28843007 ( click the link to review the publication )

Ann Surg Treat Res, 2018, 95(5):240-248

PubMed: 30402442 ( click the link to review the publication )

Oncotarget, 2018, 9(28):20075-20088

PubMed: 29732004 ( click the link to review the publication )

Oncotarget, 2018, 9(24):16701-16717

PubMed: 29682179 ( click the link to review the publication )

Oncotarget, 2018, 9(39):25630-25646

PubMed: 29876013 ( click the link to review the publication )

Oncotarget, 2018, 9(42):26834-26851

PubMed: 29928488 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(10):1226-1236

PubMed: 28945232 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(9):1116-1129

PubMed: 28846096 ( click the link to review the publication )

J Clin Invest, 2017, 127(1):153-168

PubMed: 27893461 ( click the link to review the publication )

J Clin Invest, 2017, 127(2):635-650

PubMed: 28094768 ( click the link to review the publication )

Nat Commun, 2017, 8:16078

PubMed: 28714472 ( click the link to review the publication )

Genes Dev, 2017, 31(17):1754-1769

PubMed: 28982759 ( click the link to review the publication )

Biomaterials, 2017, 144:73-83

PubMed: 28823845 ( click the link to review the publication )

Cancer Res, 2017, 77(9):2512-2521

PubMed: 28202514 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 29148970 ( click the link to review the publication )

Oncogene, 2017, 36(15):2066-2073

PubMed: 27694901 ( click the link to review the publication )

Cancer Lett, 2017, 411:19-26

PubMed: 28987383 ( click the link to review the publication )

Sci Signal, 2017, 10(499)

PubMed: 28974650 ( click the link to review the publication )

Arch Toxicol, 2017, 91(5):2191-2208

PubMed: 27807597 ( click the link to review the publication )

Eur J Immunol, 2017, 47(6):1009-1021

PubMed: 28493377 ( click the link to review the publication )

Biochem Pharmacol, 2017, 140:41-52

PubMed: 28595877 ( click the link to review the publication )
J Biol Chem, 2017, 292(36):15105-15120

PubMed: 28673964 ( click the link to review the publication )

Analyst, 2017, 142(23):4399-4404

PubMed: 29116264 ( click the link to review the publication )

Clin Immunol, 2017, 181:32-42

PubMed: 28579554 ( click the link to review the publication )

Toxicol In Vitro, 2017, 42:38-46

PubMed: 28366708 ( click the link to review the publication )

Mol Cell Biochem, 2017, 429(1-2):91-102

PubMed: 28120212 ( click the link to review the publication )

Arch Oral Biol, 2017, 73:1-6

PubMed: 27632413 ( click the link to review the publication )

Oncol Lett, 2017, 14(1):903-908

PubMed: 28693250 ( click the link to review the publication )

Asia Pac J Clin Oncol, 2017, 13(2):e144-e152

PubMed: 26552712 ( click the link to review the publication )

Oncotarget, 2017, 8(65):108522-108533

PubMed: 29312548 ( click the link to review the publication )

Oncotarget, 2017, 8(63):107206-107222

PubMed: 29291023 ( click the link to review the publication )

Oncotarget, 2017, 8(43):74299-74311

PubMed: 29088786 ( click the link to review the publication )

Anat Rec (Hoboken), 2017, 300(2):326-339

PubMed: 27486855 ( click the link to review the publication )

Thromb Haemost, 2017, 117(2):311-324

PubMed: 27929199 ( click the link to review the publication )

Oncotarget, 2017, 8(29):46801-46817

PubMed: 27086916 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 28692422 ( click the link to review the publication )

Oncotarget, 2017, 8(5):8670-8678

PubMed: 28055968 ( click the link to review the publication )

Viruses, 2017, 9(10)

PubMed: 28946654 ( click the link to review the publication )

J Clin Invest, 2016, 126(1):181-94

PubMed: 26619119 ( click the link to review the publication )

Nat Commun, 2016, 7:11190

PubMed: 27048913 ( click the link to review the publication )

Autophagy, 2016, 12(7):1083-93

PubMed: 27172402 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(5):1138-49

PubMed: 26467384 ( click the link to review the publication )

Br J Pharmacol, 2016, 173(3):471-83

PubMed: 26493374 ( click the link to review the publication )

Cell Death Dis, 2016, 7(8):e2342

PubMed: 27537525 ( click the link to review the publication )

Br J Cancer, 2016, 114(11):1219-26

PubMed: 27140314 ( click the link to review the publication )
Oncogenesis, 2016, 10.1038/oncsis.2016.33

PubMed: 27159675 ( click the link to review the publication )

J Virol, 2016, 90(5):2356-71

PubMed: 26676786 ( click the link to review the publication )

Biochim Biophys Acta, 2016, 1863(4):562-71

PubMed: 26704388 ( click the link to review the publication )

Lab Invest, 2016, 96(10):1128-37

PubMed: 27617402 ( click the link to review the publication )

Am J Cancer Res, 2016, 6(6):1345-57

PubMed: 27429848 ( click the link to review the publication )

Cancer Cell Int, 2016, 16:27

PubMed: 27042160 ( click the link to review the publication )

J Immunother, 2016, 39(3):117-26

PubMed: 26938945 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 477(4):607-13

PubMed: 27343560 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 478(1):143-148

PubMed: 27449608 ( click the link to review the publication )

Anticancer Res, 2016, 36(4):1673-82

PubMed: 27069145 ( click the link to review the publication )

Exp Ther Med, 2016, 11(2):669-673

PubMed: 26893664 ( click the link to review the publication )

Oncotarget, 2016, 7(50):83208-83222

PubMed: 27825124 ( click the link to review the publication )

Sci Rep, 2016, 6:21264

PubMed: 26887909 ( click the link to review the publication )

Oncotarget, 2016, 7(3):3520-32

PubMed: 26657288 ( click the link to review the publication )

Tumour Biol, 2016, 37(8):10839-49

PubMed: 26880588 ( click the link to review the publication )

Oncotarget, 2016, 7(51):85492-85501

PubMed: 27863431 ( click the link to review the publication )

Oncotarget, 2016, 7(6):6626-38

PubMed: 26675547 ( click the link to review the publication )

Oncotarget, 2016, 7(48):79637-79653

PubMed: 27793034 ( click the link to review the publication )

Oncotarget, 2016, 7(51):84594-84607

PubMed: 27829238 ( click the link to review the publication )

Oncotarget, 2016, 7(47):77815-77824

PubMed: 27780925 ( click the link to review the publication )

Blood, 2015, 24;126(13):1565-74

PubMed: 26254443 ( click the link to review the publication )

Nat Commun, 2015, 6:6891

PubMed: 25922916 ( click the link to review the publication )

Autophagy, 2015, 11(3):452-9

PubMed: 25715028 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(17):3995-4003

PubMed: 26015514 ( click the link to review the publication )
Proc Natl Acad Sci U S A, 2015, 112(6):E536-45

PubMed: 25624498 ( click the link to review the publication )

EMBO Rep, 2015, 16(5):618-27

PubMed: 25739811 ( click the link to review the publication )

Cancer Res, 2015, 75(24):5318-28

PubMed: 26670562 ( click the link to review the publication )

Cancer Res, 2015,

PubMed: 25432173 ( click the link to review the publication )

Cell Death Differ, 2015, 10.1038/cdd.2015.8

PubMed: 25698446 ( click the link to review the publication )

J Med Chem, 2015, 58(4):1644-68

PubMed: 25585174 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):409-21

PubMed: 25308513 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):409-21

PubMed: ( click the link to review the publication )

J Biol Chem, 2015, 290(19):12290-9

PubMed: 25829495 ( click the link to review the publication )

Cancer Cell Int, 2015, 15:34

PubMed: 25852302 ( click the link to review the publication )

Neurogastroenterol Motil, 2015, 10.1111/nmo.12521

PubMed: 25690069 ( click the link to review the publication )

Int J Oncol, 2015, 46(2):667-76

PubMed: 25434832 ( click the link to review the publication )

Eur J Pharm Sci, 2015, 70:64-71

PubMed: ( click the link to review the publication )

Eur J Pharm Sci, 2015, 70:64-71

PubMed: 25596561 ( click the link to review the publication )

Exp Cell Res, 2015, 335(1):62-7

PubMed: 26024774 ( click the link to review the publication )

Exp Cell Res, 2015, 10.1016/j.yexcr.2015.04.016

PubMed: 25936772 ( click the link to review the publication )

BMC Cancer, 2015, 15:919

PubMed: 26585594 ( click the link to review the publication )

PLoS One, 2015, 10(11):e0143685

PubMed: 26606677 ( click the link to review the publication )

Biochem Biophys Res Commun, 2015, 464(1):286-91

PubMed: 26116776 ( click the link to review the publication )

Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 2015, 10.1016/j.mrfmmm.2015.04.005

PubMed: ( click the link to review the publication )

Cell Biochem Funct, 2015, 33(5):334-40

PubMed: 26178811 ( click the link to review the publication )

Anticancer Res, 2015, 35(3):1803-8

PubMed: 25750346 ( click the link to review the publication )

Anticancer Res, 2015,

PubMed: 26637878 ( click the link to review the publication )

Oncotarget, 2015, 6(26):22624-40

PubMed: 26265439 ( click the link to review the publication )
Oncotarget, 2015, 6(34):36338-53

PubMed: 26462148 ( click the link to review the publication )

Oncotarget, 2015, 6(8):5582-96

PubMed: 25714024 ( click the link to review the publication )

Arch Pharm Chem Life Sci, 2015, 348: 1-11

PubMed: 25641608 ( click the link to review the publication )

Oncotarget, 2015, 6(1):409-26

PubMed: 25565667 ( click the link to review the publication )

Oncotarget, 2015, 6(14):12405-20

PubMed: 25915159 ( click the link to review the publication )

Hepatol Res, 2015, 45(9):1023-1033

PubMed: 25297967 ( click the link to review the publication )

Nat Commun, 2014, 5:5637

PubMed: 25472497 ( click the link to review the publication )

Autophagy, 2014, 10(10):1776-86

PubMed: 25126729 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(21):5446-55

PubMed: 25208882 ( click the link to review the publication )

Leukemia, 2014, 28(10):1960-8

PubMed: 24577530 ( click the link to review the publication )

Chem Sci, 2014, 5, 2794–2803

PubMed: ( click the link to review the publication )

Biomaterials, 2014, 16(2):R41

PubMed: 24745479 ( click the link to review the publication )

Cell Death Differ, 2014, 21(7):1170-7

PubMed: 24682005 ( click the link to review the publication )

Cell Death Differ, 2014, 10.1038/cdd.2014.158

PubMed: 25301069 ( click the link to review the publication )

Cancer Lett, 2014, 10.1016/j.canlet.2014.09.024

PubMed: 25304383 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):38-49

PubMed: 24650799 ( click the link to review the publication )

Biomaterials Science, 2014, 10.1039/C4BM00072B

PubMed: ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1291

PubMed: 24922075 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1275

PubMed: 24901046 ( click the link to review the publication )

Acta Neuropathol Commun, 2014, 10.1186/2051-5960-2-57

PubMed: 24887326 ( click the link to review the publication )

Mol Cancer Ther, 2014, 10.1158/1535-7163.MCT-13-0998

PubMed: 24739394 ( click the link to review the publication )

Mol Cancer Res, 2014, 13(12):3332-42

PubMed: 25154561 ( click the link to review the publication )

Mol Cancer Res, 2014, (4):550-9

PubMed: 24469836 ( click the link to review the publication )
J Immunol, 2014, 193(10):4914-23

PubMed: 25288570 ( click the link to review the publication )

Bone, 2014, 67:166-74

PubMed: 25016096 ( click the link to review the publication )

J Biol Chem, 2014, 289(22):15495-15506

PubMed: 24739390 ( click the link to review the publication )

J Immunother, 2014, 37(1):8-15

PubMed: 24316551 ( click the link to review the publication )

Int J Mol Sci, 2014, 15(11):20500-17

PubMed: 25387078 ( click the link to review the publication )

Int J Hyperthermia, 2014, 30(7):502-12

PubMed: 25354679 ( click the link to review the publication )

Cell Cycle, 2014, 10.4161/15384101.2014.973321

PubMed: ( click the link to review the publication )

Thromb Res, 2014, 134(6):1311-5

PubMed: 25288466 ( click the link to review the publication )

Thromb Res, 2014, 133(1):73-9

PubMed: 24268298 ( click the link to review the publication )

PLoS One, 2014, 9(9):e103015

PubMed: 25181509 ( click the link to review the publication )

PLoS One, 2014, 9(1):e84388

PubMed: 24427286 ( click the link to review the publication )

PLoS One, 2014, 9(9):e106571

PubMed: 25192188 ( click the link to review the publication )

PLoS One, 2014, 9(2):e88587

PubMed: 24523919 ( click the link to review the publication )

PLoS One, 2014, 9(8):e105049

PubMed: 25126950 ( click the link to review the publication )

PLoS One, 2014, 9(3):e91782

PubMed: 24626299 ( click the link to review the publication )

PLoS One, 2014, 9(5):e96733

PubMed: 24824755 ( click the link to review the publication )

Leuk Lymphoma, 2014, 5:1-12

PubMed: 25373508 ( click the link to review the publication )

Biomed Res Int, 2014, 2014:306718

PubMed: ( click the link to review the publication )

Mol Cancer, 2013, 12(1):42

PubMed: 23680104 ( click the link to review the publication )

Int J Cancer, 2013, 133(8):1813-24

PubMed: 23580240 ( click the link to review the publication )

J Neurosci, 2013, 33(46):18098-108

PubMed: 24227720 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e702

PubMed: 23828565 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e762

PubMed: 23928701 ( click the link to review the publication )

Br J Cancer, 2013, 108(9):1870-8

PubMed: 23558901 ( click the link to review the publication )
Cell Death Dis, 2013, 4:e690

PubMed: 23807219 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e801

PubMed: 24030153 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e742

PubMed: 23887633 ( click the link to review the publication )

Br J Haematol, 2013, 163(3):377-84

PubMed: 24033315 ( click the link to review the publication )

Br J Haematol, 2013, 161(2):245-54

PubMed: 23398569 ( click the link to review the publication )

Stem Cells Transl Med, 2013, 2(9):690-702

PubMed: 23934910 ( click the link to review the publication )

Cancer Sci, 2013, 104(6):732-9

PubMed: 23421409 ( click the link to review the publication )

Mol Cancer Res, 2013, 11(2):109-21

PubMed: 23233484 ( click the link to review the publication )

Cancer Gene Ther, 2013, 20(7):386-93

PubMed: 23788110 ( click the link to review the publication )

J Biol Chem, 2013, 288(10):6826-34

PubMed: 23329846 ( click the link to review the publication )

Apoptosis, 2013, 18(11):1403-15

PubMed: 23760752 ( click the link to review the publication )

Biomed Pharmacother, 2013, 67(7):583-91

PubMed: 23706691 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2013, 274(2):319-27

PubMed: 24321340 ( click the link to review the publication )

Int J Biochem Cell Biol, 2013, 45(5):944-51

PubMed: 23395630 ( click the link to review the publication )

PLoS One, 2013, 8(5):e63232

PubMed: 23658815 ( click the link to review the publication )

PLoS One, 2013, 8(11):e78570

PubMed: 24223823 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 437(4):565-72

PubMed: 23850692 ( click the link to review the publication )

Leuk Lymphoma, 2013, 54(2):372-80

PubMed: 22830613 ( click the link to review the publication )

Exp Dermatol, 2013, 22(8):518-23

PubMed: 23802633 ( click the link to review the publication )

Basic Clin Pharmacol Toxicol, 2013, 113(3):145-51

PubMed: 23557083 ( click the link to review the publication )

J Ovarian Res, 2013, 6(1):72

PubMed: 24103422 ( click the link to review the publication )

Cytometry A, 2013, 83(2):227-34

PubMed: 23165976 ( click the link to review the publication )

Oncotarget, 2013,

PubMed: 24334291 ( click the link to review the publication )

Blood, 2012, 120(19):3978-85

PubMed: 22927247 ( click the link to review the publication )
Mol Cell, 2012, 46(5):573-83

PubMed: 22560721 ( click the link to review the publication )

J Clin Invest, 2012, 122(6):2018-31

PubMed: 22622039 ( click the link to review the publication )

EMBO J, 2012, 31(10):2322-35

PubMed: 22510886 ( click the link to review the publication )

Oncogene, 2012, 31(26):3177-89

PubMed: 22056880 ( click the link to review the publication )

Breast Cancer Res, 2012, 14(3):R96

PubMed: 22703841 ( click the link to review the publication )

Anal Chem, 2012, 84(11):4703-10

PubMed: 22533353 ( click the link to review the publication )

Br J Haematol, 2012, 159(5):565-71

PubMed: 23025479 ( click the link to review the publication )

Mol Cancer Res, 2012, 10(3):347-59

PubMed: 22241218 ( click the link to review the publication )

J Biol Chem, 2012, 287(25):21357-70

PubMed: 22553204 ( click the link to review the publication )

J Biol Chem, 2012, 287(21):17682-92

PubMed: 22433870 ( click the link to review the publication )

Mol Endocrinol, 2012, 26(9):1508-20

PubMed: 22771494 ( click the link to review the publication )

Phytother Res, 2012, 27(6):835-40

PubMed: 22899281 ( click the link to review the publication )

BMC Cancer, 2012, 12:541

PubMed: 23171055 ( click the link to review the publication )

PLoS One, 2012, 7(8):e43158

PubMed: 22912816 ( click the link to review the publication )

PLoS One, 2012, 7(12):e52333

PubMed: 23284992 ( click the link to review the publication )

J Pharmacol Sci, 2012, 119(4):330-40

PubMed: 22814102 ( click the link to review the publication )

Blood, 2011, 117(26):7145-54

PubMed: 21562047 ( click the link to review the publication )

J Clin Invest, 2011, 121(3):1053-63

PubMed: 21317538 ( click the link to review the publication )

Leukemia, 2011, 25(11):1728-38

PubMed: 21701487 ( click the link to review the publication )

Neuro Oncol, 2011, 13(12):1265-76

PubMed: 21880625 ( click the link to review the publication )

Cancer Res, 2011, 71(13):4494-505

PubMed: 21555370 ( click the link to review the publication )

Oncogene, 2011, 30(37):3918-29

PubMed: 21460857 ( click the link to review the publication )

Am J Nephrol, 2011, 34(6):549-59

PubMed: 22123611 ( click the link to review the publication )

Cancer Chemoth Pharm, 2011, 67(3):557-67

PubMed: 20473610 ( click the link to review the publication )
PLoS One, 2011, 6(6):e20423

PubMed: 21674052 ( click the link to review the publication )

PLoS One, 2011, 6(9):e24102

PubMed: 21949692 ( click the link to review the publication )

Biochem Biophys Res Commun, 2011, 408(2):344-9

PubMed: 21514278 ( click the link to review the publication )

Curr Pharmacogenomics Person Med, 2011, 9(3):184-190

PubMed: 22162984 ( click the link to review the publication )

Mol Cancer Ther, 2010, 19(20):5591-601

PubMed: 20587662 ( click the link to review the publication )

J Biol Chem, 2010, 285(26):19910-20

PubMed: 20421300 ( click the link to review the publication )

Apoptosis, 2010, 15(10):1256-69

PubMed: 20582477 ( click the link to review the publication )

Exp Hematol, 2010, 38(10):908-921

PubMed: 20540984 ( click the link to review the publication )

产品安全说明书

Bcl-2抑制剂选择性比较

生物活性

产品描述

特性

ABT-737是第一代抗凋亡BCL-2家族蛋白小分子抑制剂。

靶点

Bcl-2 ^[1] (Cell-free assay)	Bcl-xL ^[1] (Cell-free assay)	Bcl-w ^[1] (Cell-free assay)	Bcl-B ^[1] (Cell-free assay)
30.3 nM(EC50)	78.7 nM(EC50)	197.8 nM(EC50)	1.82 μM(EC50)

体外研究

ABT-737降低BCL-2/BAX异质二聚体,而诱导HL60细胞凋亡,但是对细胞周期分布没有抑制效果。ABT-737也诱导细胞色素C从线粒体中释放，促进BAX构象改变，BAX与凋亡相关。在白血病模型中，ABT-737按30 mg/kg处理，阻断53%白血病负荷，且使鼠寿命明显延长。ABT-737不会导致血细胞数和血清组成发生异常。^[1]通过使Mcl-1失活而使抵抗细胞（Hela和MCF-7）对ABT-737敏感。当Mcl-1无效时，ABT-737也导致BAX/BAK-依赖的细胞色素C释放。ABT-737延长携带BCL-2肿瘤的鼠寿命。^[2]ABT-737从BCL2’s BH3结合袋取代BIM,使BIM激活BAX,诱导线粒体透化作用,快速致死慢性淋巴细胞性白血病(CLL)细胞。^[3] Noxa正向调节增强H196细胞对ABT-737敏感性。ABT-737抑制多种SCLC细胞系，包括NCI-H889, NCI-H1963, NCI-H1417, NCI-H146等的增殖，并诱导细胞凋亡。最近研究显示，ABT-737作用于ATLL细胞，明显诱导HTLV-1感染的T细胞凋亡。ABT-737按100 mg/kg剂量作用于ATLL鼠模型显示出强抗癌活性。^[5]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
OCI-Ly1	M{nOc2NmdGxiVnnhZoltcXS7IFHzd4F6	NYG3WllZOjVyIH7NxsA>	NGLQ[204OiCq	NIDLUYRFVVOR	MnfFZ4F2e2WmIEm3KUBtd3O\|IH;mJJZq[WKrbHn0fUBqdiClZXzsd{B1emGwc3\lZ5Rm\CC5aYToJGJEVDZic3nSUmE>	MofKNlY3PTd{OEi=
KG1a	MnXOR4VtdCCYaXHibYxqfHliQYPzZZk>	NF7jOooxNTFyIN88US=>	NVPP[mNZOjRiaB?=	MkfLSG1UVw>?	MUTJR\|UxRTdwNkig{txONCCmZXPy[YF{\XNiY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	MYqyOlU2OjdzMh?=
Kasumi-1	MkDJR4VtdCCYaXHibYxqfHliQYPzZZk>	M2rkPFAuOTBizszN	Mo\4NlQhcA>?	NVLtfGRITE2VTx?=	M{jiVGlEPTB;ND64O{DPxE1uIHTlZ5Jm[XOnczDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	M1TlZVI3PTV{N{Gy
KG1a	NGXzO3NCeG:ydH;zbZMhSXO\|YYm=	NXm5dIY6OC1zMDFOwG0>	NFP6S3MzPCCq	NXToNIJ3TE2VTx?=	NWDLRmRmcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	M3rR[\|I3PTV{N{Gy
Kasumi-1	M3\LRmFxd3C2b4Ppd{BCe3OjeR?=	M1HsUVAuOTBizszN	MWqyOEBp	M13wfmROW09?	M2X0Volv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	NWPLXoVZOjZ3NUK3NVI>
MC-3	MnG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIfsdWc2NzFyL{KwJO69VQ>?	Mn\BNlQhcA>?	MYHEUXNQ	NEXC[ZBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	Ml3mNlY1PDd4MUW=
HN22	NXfrWIZMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUiyMlUwPy53L{KyMlUh\|ryP	MVSyOEBp	NGrienRFVVOR	NHrUPJlqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	Mmn5NlY1PDd4MUW=
MC-3	NFuyeZZCeG:ydH;zbZMhSXO\|YYm=	NY[4PWczPS9zMD:yNEDPxE1?	MnrvNlQhcA>?	MVLEUXNQ	NIL6eJlqdmS3Y3XzJINie3Cjc3WtcYVlcWG2ZXSgZZBweHSxc3nz	M4m3c\|I3PDR5NkG1
HN22	M{DzZ2Fxd3C2b4Ppd{BCe3OjeR?=	MWCyMlUwPy53L{KyMlUh\|ryP	NYixU5EzOjRiaB?=	Mo\sSG1UVw>?	MnvjbY5lfWOnczDjZZNx[XOnLX3l[IlifGWmIHHwc5B1d3Orcx?=	M3nTOVI3PDR5NkG1
MOLT-4	NEDYfnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXHxW\|lNOTBvNUCwNEBvVQ>?	M3;0WFczKGh?	MlPsSG1UVw>?	MmrVTWM2OD1yLkG5PEDPxE1?	M4rqdVI3Ozl{M{Oy
RS4;11	Mn3lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFzwOpAyOC13MECwJI5O	NF;sW5g4OiCq	NXW1dlF5TE2VTx?=	MmTBTWM2OD1yLkCwNkDPxE1?	M2ewbVI3Ozl{M{Oy
JURKAT	NFzpUGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVzK[2VXOTBvNUCwNEBvVQ>?	NFTkVm04OiCq	NGG3ZmNFVVOR	NXG1ZlJ4UUN3ME22OkDPxE1?	NHfBRWIzPjN7MkOzNi=>
CEM R	NHfqV4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHr6fpYyOC13MECwJI5O	NXnFcI9iPzJiaB?=	NIDSUW1FVVOR	MVXJR\|UxRTVwNDFOwG0>	M{CyUlI3Ozl{M{Oy
CEM S	NXXjd2pWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;ZVVExNTVyMECgcm0>	MUm3NkBp	NH3u[FZFVVOR	NXzjR3A5UUN3ME2xNk4yKM7:TR?=	NULBSFgzOjZ\|OUKzN\|I>
MOLT-4	NVP6S29uSXCxcITvd4l{KEG\|c3H5	MlO4NVAuOTByMDDuUS=>	NGr2O\|QzPCCq	MnrRSG1UVw>?	MWDjZZV{\XNidHjlJINt\WG4YXflJI9nKEKlbD2yJIFv\CC2aHWg[I94dnKnZ4XsZZRqd25ib3[gRoNtNXiOIHHu[EBO[2xvMR?=	M1O0eFI3Ozl{M{Oy
CEM S	NFmwVnZCeG:ydH;zbZMhSXO\|YYm=	NHuyS5oyOC1zMECwJI5O	MonxNlQhcA>?	NEfhZlhFVVOR	NGjFN4Jk[XW\|ZYOgeIhmKGOuZXH2ZYdmKG:oIFLjcE0zKGGwZDD0bIUh\G:5boLl[5Vt[XSrb36gc4YhSmOuLYjMJIFv\CCPY3ytNS=>	MUGyOlM6OjN\|Mh?=
JURKAT	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4WxW\|ExOC1zMECwJI5O	NXL1S49IPDhiaB?=	NEHxb2JFVVOR	NULxNmtrUUN3ME25OVXDuTlwMzDuUS=>	MWKyOlE4OjJ4OR?=
LOUCY	NIG1[IlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MknTNVAxNTFyMECgcm0>	Mn;lOFghcA>?	NVfmTYtqTE2VTx?=	NYHSbmJqUUN3ME2zNk45yrFzMD65JI5O	NHX6b\|IzPjF5MkK2PS=>
WM-115	M3HJVWNmdGxiVnnhZoltcXS7IFHzd4F6	M2n0T\|ExOMLibl2=	MkXTO\|IhcA>?		MmCw[Y5p[W6lZYOgZ5Vz[3WvaX6tbY5lfWOnZDDhcpRqNXO3co\peoFtyqB?	MV[yOlEyPjd5Nh?=
B16	M2TrRmNmdGxiVnnhZoltcXS7IFHzd4F6	MmTONVAxyqCwTR?=	MUO3NkBp		NF7pb2FmdmijbnPld{BkfXKldX3pck1qdmS3Y3XkJIFvfGlvc4Xyeol3[W{EoB?=	MmfNNlYyOTZ5N{[=
HL-60	NF\ZVmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MVK3NkBp		NHiwdoRKSzVywrC9JFExNjdibl2=	MXWyOlA1PTZyOR?=
MOLM-13	MnPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{LmdFczKGh?		MonQTWM2OMLiPTCyO{46KG6P	MoGzNlYxPDV4MEm=
OCI-AML3	NHrTVXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NUPaNpRsPzJiaB?=		MlzxTWM2OMLiPTCxPVUxKG6P	M3H5NlI3ODR3NkC5
BCWM.1	M4DON2Fxd3C2b4Ppd{BCe3OjeR?=	MWqwMVEvPiEQvF2=	NHLafHozPCCq		MYLpcoR2[2W\|IHPlcIwh[XCxcITvd4l{	M3HxV\|I2QDl\|Mkmw
MWCL-1	M3;WSGFxd3C2b4Ppd{BCe3OjeR?=	MXGwMVEvPiEQvF2=	MlfWNlQhcA>?		M1HYRYlv\HWlZYOgZ4VtdCCjcH;weI9{cXN?	NGHIcoQzPTh7M{K5NC=>
MM.1s	M1TPfWFxd3C2b4Ppd{BCe3OjeR?=	NU\1S\|NbOC1zLk[g{txO	NIf6SIEzPCCq		MYXpcoR2[2W\|IHPlcIwh[XCxcITvd4l{	NWf4UZkxOjV6OUOyPVA>
HCT116	Mm\OSpVv[3Srb36gRZN{[Xl?	MUOzM\|ExKM7:TR?=	NXP6NJJ5OTMEoHlCpC=>	NIHIZnFFVVOR	MoHXbY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJGxEO0JvSVmgZ49vfmW{c3nvckBidmRiU2HTWG0yKGSnZ4Lh[IF1cW:w	NI\yWWszPTdzNUCyPC=>
HCT116 BAX BAK1 DKO	NEDh[5dHfW6ldHnvckBCe3OjeR?=	NYXZPY06Oy9zMDFOwG0>	NFHSUI4yOsLiaNMg	NVzSbodsTE2VTx?=	M3P1VYlv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDpcoNz\WG\|ZTDpckBNSzOELVnJJINwdn[ncoPpc44h[W6mIGPRV3ROOSCmZXfyZYRifGmxbh?=	MmHrNlU4OTVyMki=
HCT116	MXfGeY5kfGmxbjDBd5NigQ>?	M1u1TVExKM7:TR?=	M{[yOVEzyqCqwrC=	M1nFTWROW09?	M2ThVYlv[3KnYYPld{BITlBvTFOzRkBxfW6ldHG=	M{fQNlI2PzF3MEK4
HCT116 BAX BAK1 DKO	MYLGeY5kfGmxbjDBd5NigQ>?	NI\YTmMyOCEQvF2=	NI[1Z\|AyOsLiaNMg	MnnwSG1UVw>?	NVzFfnpScW6lcnXhd4V{KEeIUD3MR\|NDKHC3bnP0ZS=>	M1XxO\|I2PzF3MEK4
HCT116	NV;obHpVSXW2b4DoZYd6KEG\|c3H5	MX2xNEDPxE1?	MoTDNVLDqGkEoB?=	MWnEUXNQ	NGjwc3pqdmS3Y3XzJIEh[2:vcHzleIUh[XW2b4DoZYdq[yC{ZYPwc45{\Q>?	NV7YXYsxOjV5MUWwNlg>
HCT116 BAX BAK1 DKO	M1PFR2F2fG:yaHHnfUBCe3OjeR?=	MXqxNEDPxE1?	MnvvNVLDqGkEoB?=	M{e3bmROW09?	M2rMWYlv\HWlZYOgZUBkd22ybHX0[UBifXSxcHjh[4lkKHKnc4DvcpNm	MWiyOVcyPTB{OB?=
U937	NXHHcGFTSXCxcITvd4l{KEG\|c3H5	MV[wMlEzPS1{IN88US=>	MX6yOEBp		NIPOVWlmdmijbnPld{BFUEFxWD2xNU1qdmS3Y3XkJIFxd3C2b4Ppdy=>	NYfJ[JRMOjV5MUSwNlQ>
U937	Mn7iRZBweHSxc3nzJGF{e2G7	M1fWVlAvPSEQvF2=	MYCyOEBp		NWPoPHV2\W6qYX7j[ZMh[2ynYY\h[4Uhd2ZiUFHSVEBidmRiY3HzdIF{\S1\|IHHzJJdmdGxiYYOgUo95[SCuZY\lcC=>	MmnWNlU4OTRyMkS=
HL-60 AAA-Bcl-2	MWDBdI9xfG:\|aYOgRZN{[Xl?	M2XFfFAuPSEQvF2=	NGPYcXk1QCCq		MULJR\|UxRTBwOEeg{txu97zOaX7keYNmeyClZXzsJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	MnjtNlU4OTF2NkC=
HL-60 EEE-Bcl-2	MX;BdI9xfG:\|aYOgRZN{[Xl?	NYjrWY04OC13IN88US=>	NFn3W3I1QCCq		NIj4bHJKSzVyPUWg{txu97zOIHnu[JVk\XNiY3XscEBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NGniRXkzPTdzMUS2NC=>
U87	Mn\TSpVv[3Srb36gRZN{[Xl?	NI\rW2s2OCEQvF2=	NYqyT2w{OjRiaB?=		NIrNPG5z\WS3Y3XzJJRp\SCvUl7BJIV5eHKnc4Ppc44hdGW4ZXzzJI9nKE2PUD2yMEBOVVBvMUSgZY5lKEKlbD2y	NFv3N5AzPTZ4N{[2Ny=>
K562	NEO0N3hE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MmrWNU0yOCEQvF2=	M33XdFQ5KGh?	M{PzUWROW09?	NV7YU2hbUUN3ME2yOk44KM7:TR?=	MlfHNlU2QTZ3NkG=
K562/Mcl -1-IRESBim	MmOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXrJR\|UxRTlwMzFOwG0>	NF[2SmYzPTV\|NUmwNC=>
K562/Bcl- 2-IRESBim	M1HYeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1fjVmlEPTB;MD6zOUDPxE1?	NW\rZopKOjV3M{W5NFA>
Jurkat	M3;MeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3m1dmlEPTB;MD62OkDPxE1?	NYP1bGxzOjV3M{W5NFA>
JurkatΔBak	NIm0Z4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV61OFl7UUN3ME61NEDPxE1?	MUOyOVU{PTlyMB?=
HL60/VCR	NHLFOZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXLSZVJEUUN3ME6xNFAh\|ryP	MmH0NlU2OzV7MEC=
Kasumi-1	NW\sTIEzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml;rTWM2OD1yLkCxJO69VQ>?	NFrwOnAzPTV\|NUmwNC=>
Kasumi-1/ABT	MnL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXfJR\|UxRTBwNUGg{txO	MnTlNlU2OzV7MEC=
THP-1	MmjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MljTTWM2OD1zLkK3JO69VQ>?	MljvNlU2OzV7MEC=
U937	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYn1fXd[UUN3ME21MlI6KM7:TR?=	NViwT3RYOjV3M{W5NFA>
C1498	Mn3qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXrJR\|UxRTZwMUOg{txO	NVvwPZBGOjV3M{W5NFA>
RPMI 8226	Mk\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2\4eGlEPTB;MD6yOUDPxE1?	M2XlVlI2PTN3OUCw
MM.1S	M1zFZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX7JR\|UxRTBwNECg{txO	NVqxe402OjV3M{W5NFA>
NCI-H929	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlXETWM2OD1zNT6yNUDPxE1?	NFrPb3AzPTV\|NUmwNC=>
U266	M4q5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{jseGlEPTB;MD62PEDPxE1?	NWfQeG1WOjV3M{W5NFA>
MCF-7	NYLLSYZQS2WubDDWbYFjcWyrdImgRZN{[Xl?	M{jJWlUh\|ryP	NYnlfpVnPDhiaB?=	NW\Ne\|ZPTE2VTx?=	MUDlcohidmOnczD0bIUhe2Wwc3n0bZZqfHlidH:gc5IhemGmaXH0bY9v	M2HSeVI2PDB7MUK0
MCF-7	MWLBdI9xfG:\|aYOgRZN{[Xl?	MmnDOUDPxE1?	M2m0clQwOjRxNEigbC=>	NF7p[npFVVOR	M3f6Nolv[3KnYYPld{B1cGViY3zlZZZm\CCSQWLQ	NV;aSIVyOjV2MEmxNlQ>
MCF-7	NX3IfmhCTnWwY4Tpc44hSXO\|YYm=	M2LBO\|Uh\|ryP	M3\yVFI1KGh?	M3v3OmROW09?	NVnmZpFt\W6qYX7j[ZMhfGinbHX2[Ywhd2ZiTXPsMVEh\XiycnXzd4lwdsLi	Mo\aNlU1ODlzMkS=
MDA-MB 231	M{DMXGZ2dmO2aX;uJGF{e2G7	NX73Rmc6PSEQvF2=	MmXzNlQhcA>?	MYPEUXNQ	NVrYeoZp\W6qYX7j[ZMhfGinbHX2[Ywhd2ZiTXPsMVEh\XiycnXzd4lwdsLi	NELlWVczPTRyOUGyOC=>
ZR-75-1	M{DqbWZ2dmO2aX;uJGF{e2G7	M3LKNlUh\|ryP	M3LH[lI1KGh?	NInRW3pFVVOR	NGPUbGVmdmijbnPld{B1cGWuZY\lcEBw\iCPY3ytNUBmgHC{ZYPzbY9vyqB?	MVKyOVQxQTF{NB?=
A549	M1frNmNmdGxiVnnhZoltcXS7IFHzd4F6	M1LyfFAuOjBizszN	MnK4O\|IhcA>?	NXXNbGxyTE2VTx?=	M17F[4Rm[3KnYYPld{B1cGViY3XscEB{fXK4aY\hcEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldkBkd22kaX7l[EB4cXSqIHHzdIlzcW5?	NGTpTGgzPTN6OEe2Ni=>
H1299	NWPBV5pWS2WubDDWbYFjcWyrdImgRZN{[Xl?	NEfxNWYxNTJyIN88US=>	NI\SfIU4OiCq	Mle5SG1UVw>?	NIXHU2hl\WO{ZXHz[ZMhfGinIHPlcIwhe3W{dnn2ZYwhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIh[2:vYnnu[YQhf2m2aDDhd5Bqemmw	NHrz[XUzPTN6OEe2Ni=>
HO-8910	M3HJZmNmdGxiVnnhZoltcXS7IFHzd4F6	M3zUXlAuOjBizszN	NEjVU5A4OiCq	NYDKbVFjTE2VTx?=	NHnjZppl\WO{ZXHz[ZMhfGinIHPlcIwhe3W{dnn2ZYwhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIh[2:vYnnu[YQhf2m2aDDhd5Bqemmw	NInNb2EzPTN6OEe2Ni=>
HT-29	NX\HW2EzS2WubDDWbYFjcWyrdImgRZN{[Xl?	M12yflAuOjBizszN	MmrOO\|IhcA>?	MWXEUXNQ	MnXB[IVkemWjc3XzJJRp\SClZXzsJJN2en[rdnHsJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJINwdWKrbnXkJJdqfGhiYYPwbZJqdg>?	NXiwN2p7OjV\|OEi3OlI>
HCT-116	MUnD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	M4q1RlAuOjBizszN	NWXudFRwPzJiaB?=	NHvrT2JFVVOR	NVHtSlF6\GWlcnXhd4V{KHSqZTDj[YxtKHO3co\peoFtKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzKGOxbXLpcoVlKHerdHigZZNxcXKrbh?=	M1uwb\|I2Ozh6N{[y
A549	M3XtVmFxd3C2b4Ppd{BCe3OjeR?=	NEnGW\|EzOCEQvF2=	MWG0PEBp	Mn\VSG1UVw>?	MnrFbY5lfWOnczDhdI9xfG:\|aYOgd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJIF{eGm{aX6=	M1PmXlI2Ozh6N{[y
H1299	MVfBdI9xfG:\|aYOgRZN{[Xl?	MnjnNlAh\|ryP	M3q5T\|Q5KGh?	MXjEUXNQ	MnnxbY5lfWOnczDhdI9xfG:\|aYOgd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJIF{eGm{aX6=	NYHCS2xJOjV\|OEi3OlI>
Sc-1	NFz4blZE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MlPCNE4xODBzLUGg{txO	MmPxPVYhcA>?		MX3k[YNz\WG\|ZYOgeIhmKGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NFHuUJozPTN5M{WwPC=>
OcI-LY18	M1X5OWNmdGxiVnnhZoltcXS7IFHzd4F6	M1PLWlAvODByMT2xJO69VQ>?	NWnGNYx5QTZiaB?=		NWLF[pRF\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	MnXNNlU{PzN3MEi=
RL	MnXER4VtdCCYaXHibYxqfHliQYPzZZk>	NXvWPFQyOC5yMECxMVEh\|ryP	MljjPVYhcA>?		NV3yemtT\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	MYiyOVM4OzVyOB?=
RKO	NEDBO2dE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NH7IPZkxNTFyIN88US=>	Mn;rNlTjiImqwrC=	MkjpSG1UVw>?	NGTu[WpKSzVyPvMAjVI26oDLwsXN	MXqyOVMxPDN6Mx?=
Caco-2	NITzdVFE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MXKwMVExKM7:TR?=	NWDiUJRKOjUkgJnoxsA>	NHf0RYRFVVOR	MlfQTWM2OD1zOT635qCKyrWP	M2fobFI2OzB2M{iz
DLD1	MU\D[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NXjwZYhGOC1zMDFOwG0>	MnPpNlTjiImqwrC=	M4rENWROW09?	NF3FdVRKSzVyPUG4Mlc56oDLwsXN	MX:yOVMxPDN6Mx?=
LS411N	M{Xk[GNmdGxiVnnhZoltcXS7IFHzd4F6	M1PWZVAuOTBizszN	M1K3dVI16oDLaNMg	NWXpdnJrTE2VTx?=	NUTsdo9RUUN3ME2xNU41P+LCidM1US=>	MX2yOVMxPDN6Mx?=
SW620	MnPlR4VtdCCYaXHibYxqfHliQYPzZZk>	MnTENE0yOCEQvF2=	NH7MeYwzPOLCiXlCpC=>	NUiyNIplTE2VTx?=	M{[xPWlEPTB;MUKuNlTjiIoEtV2=	NWPUfJhsOjV\|MESzPFM>
HCT116	M2Pq[mNmdGxiVnnhZoltcXS7IFHzd4F6	MorCNE0yOCEQvF2=	MUWyOQKBkWkEoB?=	NEDSWZBFVVOR	MofRTWM2OD1{MD60PgKBkcL3TR?=	NF:3VJIzPTNyNEO4Ny=>
HaCaT	M3ziTGNmdGxiVnnhZoltcXS7IFHzd4F6	MWSwMlEwOS9zMDFOwG0>	MV2yOEBp	NYCxcHp6TE2VTx?=	M1X5SoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NVXYdHA5OjV{MUC3PVU>
A5-RT3	MlPsR4VtdCCYaXHibYxqfHliQYPzZZk>	MnnKNE4yNzFxMUCg{txO	M4niO\|I1KGh?	NIfoSYxFVVOR	MUXk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	NIe2OJIzPTJzMEe5OS=>
HaCaT	NGXxNldHfW6ldHnvckBCe3OjeR?=	NWW5ZmJyOTEkgJpOwG0>	M1Hqd\|I1NzR6IHi=	MVrEUXNQ	MmfqbY5lfWOnczDNUXAh[W6mIFTORUBnemGpbXXueIF1cW:w	MlT3NlUzOTB5OUW=
A5-RT3	NF;1WIdHfW6ldHnvckBCe3OjeR?=	MYGxNQKBkc7:TR?=	MX[yOE81QCCq	MmLzSG1UVw>?	NXHJV2lWcW6mdXPld{BOVVBiYX7kJGRPSSCocnHncYVvfGG2aX;u	M{DKbFI2OjFyN{m1
A5-RT3	MYTGeY5kfGmxbjDBd5NigQ>?	MUK1JO69VQ>?	Mm\6OkBp	MmPVSG1UVw>?	Mn3FbY5lfWOnczD0bIUhemWuZXHz[UBw\iCvaYTvZ4hwdmS{aXHsJJBzd3SnaX7zJIFv\CC{ZXT1Z4V{KGOub37v[4VvcWNic4Xyeol3[WxiaX6gZUBk[XOyYYPlMYlv\GWyZX7k[Y51KG2jbn7ldi=>	Mo\2NlUzOTB5OUW=
U266	MnexSpVv[3Srb36gRZN{[Xl?	M{DjelUxOC95NUCgcm0>	NGfFSZgzPC92ODDo	MojhSG1UVw>?	Mlv5[I94dnKnZ4XsZZRmeyCEaX2sJJBzcW6laYDhcIx6KHSqZTDFUEBqe2:ob4Lt	NUXiblQzOjV{MEi4PFg>
RPMI8226	MVrGeY5kfGmxbjDBd5NigQ>?	NXTJd5lGPTByL{e1NEBvVQ>?	MonENlQwPDhiaB?=	MnzlSG1UVw>?	M4nxboRwf26{ZXf1cIF1\XNiQnntMEBxemmwY3nwZYxtgSC2aHWgSWwhcXOxZn;ycS=>	NULwbJBvOjV{MEi4PFg>
MM.1S	MmjESpVv[3Srb36gRZN{[Xl?	MkjyOVAxNzd3MDDuUS=>	MYeyOE81QCCq	MWPEUXNQ	NWjCfWJR\G:5boLl[5Vt[XSnczDCbY0tKHC{aX7jbZBidGy7IITo[UBGVCCrc3;mc5Ju	M{PF[FI2OjB6OEi4
Clone A	NFjEcGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV[wMlLjiJN4MDFOwG0>	MnS2O\|IhcA>?	Mo\OSG1UVw>?	MonDTWM2OD15LkWg{txO	MoHhNlUzODh6OEK=
CX-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVP6U2ROOC5{4pETOlAh\|ryP	M33vNlczKGh?	M1XzdmROW09?	M164WGlEPTB;MT64JO69VQ>?	NIXtXYszPTJyOEi4Ni=>
LS174T	NFvYVotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3\2TlAvOuLCk{[wJO69VQ>?	NUHrSZdQPzJiaB?=	MVzEUXNQ	M4TC[GlEPTB;MUiuN{DPxE1?	MYmyOVIxQDh6Mh?=
HT29	MXPBdI9xfG:\|aYOgRZN{[Xl?	NW\qUJpwOS93L{GwJO69VQ>?	MoPHOFghcA>?		NXr6SGtW[2G3c3XzJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	M4LmTFI2OTl{MUi4
SW480	M1fufGFxd3C2b4Ppd{BCe3OjeR?=	NYTLVG15OS93L{GwJO69VQ>?	Mn33OFghcA>?		M{jVZoNifXOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NWDoVIQ6OjVzOUKxPFg>
Colo205	NEX5SnVCeG:ydH;zbZMhSXO\|YYm=	NFzFbIYyNzVxMUCg{txO	NGC4SIM1QCCq		Mn;JZ4F2e2W\|IHPlcIwh\GWjdHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	MnzWNlUyQTJzOEi=
Caco2	MYTBdI9xfG:\|aYOgRZN{[Xl?	NH20PWcyNzVxMUCg{txO	NIP3UI81QCCq		Mm[wZ4F2e2W\|IHPlcIwh\GWjdHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	MkjWNlUyQTJzOEi=
PCI-13	NH\4XpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MkLrO\|IhcA>?	MmXWSG1UVw>?	MlvGS2k2OD1zNTFCtUAyNjhizszN	NGX3XZYzPTF\|OUO4Oy=>
PCI-15B	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NVLUO2FFPzJiaB?=	NIHDS2NFVVOR	M3r3NWdKPTB;MUGgxtEhPC53IN88US=>	MUmyOVE{QTN6Nx?=
UM-SCC22B	NGXjfGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NU\MSlFvPzJiaB?=	NUTkR2wzTE2VTx?=	M3fzNmdKPTB;MUmgxtEhOi57IN88US=>	MnvmNlUyOzl\|OEe=
UM-SCC47	Mn\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4PYZlczKGh?	NWPvc4cyTE2VTx?=	M{nXWGdKPTB;MUmgxtEhOTJwMzFOwG0>	M2[zZlI2OTN7M{i3
93-VU-147T	NWLIcZpMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NX32Roh3PzJiaB?=	MlnWSG1UVw>?	M1TzXmdKPTB;ND6zJOKyKDNwNTFOwG0>	NH:yTJQzPTF\|OUO4Oy=>
UD-SCC2	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M2DBWlczKGh?	MWrEUXNQ	MoT6S2k2OD1{ODFCtUAzNjlizszN	MYeyOVE{QTN6Nx?=
UPCI:SCC90	NYPmSoRJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NIrEO\|A4OiCq	NIqxZnVFVVOR	MkjDS2k2OD14Lk[gxtEhOS53IN88US=>	NYS3elFHOjVzM{mzPFc>
RPMI-8226	M3\3S2NmdGxiVnnhZoltcXS7IFHzd4F6	Mk\MNVI2NzJ3MD:1NFAhdk1?	MXy0PIjDqA>?	NYTBUoJPTE2VTx?=	MWXk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	Mle1NlUxODh{MEK=
OPM-2	MYDD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MV:xNlUwOjVyL{WwNEBvVQ>?	NV3CS\|JVPDiqwrC=	NWLTS3lbTE2VTx?=	NGXQXHVl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NVHSb25lOjVyMEiyNFI>
RPMI-8226	MkPTRZBweHSxc3nzJGF{e2G7	NV2xU3J3OTJ3L{K1NE82ODBibl2=	M{jpTFQ5cMLi	MUDEUXNQ	Ml3pbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	MWCyOVAxQDJyMh?=
OPM-2	MmT4RZBweHSxc3nzJGF{e2G7	MVWxNlUwOjVyL{WwNEBvVQ>?	MVS0PIjDqA>?	MU\EUXNQ	MWXpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	MXiyOVAxQDJyMh?=
COG-LL-319	MVHGeY5kfGmxbjDBd5NigQ>?	NETGfIwyODBibl2=	MlzZNU8{NzZiaB?=	MkDGSG1UVw>?	MYrpcoR2[2W\|IHPhd5Bie2VvZHXw[Y5l\W62IF3jcE0yKGOuZXH2ZYdm	NX:0doo5OjR7NUG0O\|I>
RS4;11	MX7GeY5kfGmxbjDBd5NigQ>?	NHGwXJIyODBibl2=	MV2xM\|MwPiCq	MmTkSG1UVw>?	MX\pcoR2[2W\|IHPhd5Bie2VvZHXw[Y5l\W62IF3jcE0yKGOuZXH2ZYdm	NI\LfVkzPDl3MUS3Ni=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	PARP / c-PARP / cleaved caspase 3 ; PubMed: 21393866 J Clin Invest H146 cells were preincubated in normoxia or hypoxia (1% O2) for 18 hours prior to treatment with ABT-737 (89.1 nM ), after which cells were harvested for protein analysis by Western blot. Hif-1a; PubMed: 22006676 Mol Cancer Ther Representative western blots for HIF-1α, PARP and cleaved caspase 3 in response to 24-72 hr exposure to ABT-737 in varying concentration in normoxia and hypoxia in 4 neuroblastoma cell lines. Actin is shown as a loading control. Blots are representative of 3 independent experiments. γ-H2AX / p-ATM; PubMed: 21084274 Cancer Res Induction of γ-H2AX and p-ATM by ABT-737. Cells were treated with 10 µmol/L ABT-737 for 24 hours and then maintained in fresh media for 1 or 2 more days prior to Western blot analysis.	21393866 22006676 21084274
Immunofluorescence	cytochrome C; PubMed: 26447615 Oncotarget Immunocytochemistry revealed the release of mitochondrial cytochrome c (green) into the cytoplasm after ABT-737 exposure (20 μM in MC-3 cells and 22.5 μM in HN22 cells) for 24 hr. MitoTracker (red) staining labels mitochondria within each field. Bax; PubMed: 26447615 Oncotarget Immunocytochemistry revealed the mitochondrial translocation of Bax from the cytoplasm after ABT-737 treatment (20 μM in MC-3 cells and 22.5 μM in HN22 cells) for 24 hr. MitoTracker (red) staining labels mitochondria within each field C. To assess whether ABT-737 treatment has an effect on the dimerization of Bax, the levels of dimeric Bax were measured with or without ABT-737 treatment in MC-3 and HN22 cells. Bim; PubMed: 26447615 Oncotarget Immunocytochemistry revealed the mitochondrial translocation of Bim from the cytoplasm after ABT-737 treatment (20 μM in MC-3 cells and 22.5 μM in HN22 cells) for 24 hr. MitoTracker (red) staining labels mitochondria within each field. AIF; PubMed: 25034785 Cell Death Differ localization of apoptosis inducing factor (AIF) in LCSC pre-stained with Mitotracker Red and untreated or treated with 500 nM ABT-737 for 48 h. Magnification × 60, zoom × 3, bar 20 μm. p65 ; PubMed: 28846096 Nat Cell Biol BCL-xL dependent SVEC cells were treated with ABT-737 (10 μM) +/- Q-VD-Oph (30 μM) for 1 h, immunostained for p65 and analysed by confocal microscopy. TNF (20 ng/ml) was used as positive control for p65 nuclear translocation. Scale bar represents 30μM. Representative images from three independent experiments.	26447615 25034785 28846096
Growth inhibition assay	Cell viability; PubMed: 22311987 J Biol Chem Stably transfected K562 cells were treated with increasing concentrations of ABT-737, obatoclax, or maritoclax for 24 h. Cell viability was determined by measuring intracellular ATP levels with the CellTiter Glo assay.	22311987
ELISA	IL-6 / IL-8; PubMed: 21084274 Cancer Res The secretion of IL-6 and IL-8 in PV-10 cells treated with DMSO, ABT-737 or enantiomer for 24 hours was determined by ELISA.	21084274

体内研究

ABT-737按30 mg/kg剂量作用于白血病模型，抑制白血病负担值达53% , 且明显延长鼠寿命。ABT-737不会引起血细胞数和血浆化学性质发生变话。^[1] ABT-737延长移植BCL-2传感肿瘤的鼠寿命。^[2] ABT-737按100 mg/kg剂量作用于ATLL鼠模型具有强抗癌活性。^[5]

激酶实验： ^[1]	- 合并荧光偏振实验: 测定GST-BCL-2蛋白家族与FITC-BIM BH3域结合的亲和力。100 nM GST-BCL-2家族融合蛋白和不同浓度 ABT-737在PBS温育2分钟。然后，加入20 nM FITC-BIM BH3 肽。进行荧光偏振，测定IC50值。
细胞实验： ^[4]	- 合并 Cell lines: SCLC细胞系，包括NCI-H889, NCI-H1963, NCI-H1417, NCI-H146, NCI-187, DMS79, NCI-1048, NCI-H82, NCI-H196, H69AR,和DMS114 Concentrations: 0.001-10 μM Incubation Time: 48小时 Method: SCLC细胞在含10%人血浆的 100 μL 组织培养基的96孔培养板上处理48小时，使用MTS测定存活细胞。 (Only for Reference)
动物实验： ^[1]	- 合并 Animal Models: 注射ER细胞的Scid 鼠 Dosages: 20 mg/kg和30 mg/kg Administration: 腹腔注射 (Only for Reference)

参考文献

- 合并

溶解度 (25°C)

体外	DMSO	100 mg/mL (122.93 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 2%DMSO+40%PEG300+5%Tween80+53%ddH2O	2mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download ABT-737 SDF

分子量	813.43
化学式	C₄₂H₄₅ClN₆O₅S₂
CAS号	852808-04-9
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
What’s the recommended method about reconstitution of the compound for in vivo animal study?
回答：
For oral administration, we suggest the vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W, at up to 30mg/ml; For injection, ABT-737 can be dissolved in 2% DMSO/50% PEG 300/5% Tween 80/ddH2O at 2.5 mg/ml.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

选择性强的Bcl-2抑制剂

ABT-199 (GDC-0199) : Bcl-2-selective, K_i<0.01 nM.
活性最高的Bcl-2抑制剂

ABT-263 (Navitoclax) : Bcl-xL, K_i≤ 0.5 nM; Bcl-2, K_i≤ 1 nM; Bcl-w, K_i≤ 1 nM.
用于临床的Bcl-2抑制剂

Obatoclax Mesylate (GX15-070) : Phase II for leukemia, lymphoma, myelofibrosis, and mastocytosis.
最新的Bcl-2家族激活剂

BAM7 : Direct and selective activator of proapoptotic Bax with EC50 of 3.3 μM.

研究领域

产品类型

定制您的化合物库

ABT-737

客户使用Selleck生产的ABT-737发表文献272篇：

产品安全说明书

Bcl-2抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download ABT-737 SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

技术支持

常见问题及建议解决方法

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

相关Bcl-2产品